Trav @hypergrowth102 · 03 Sep 2026
“We also believe ABCL-635’s success supports the quality of $ABCL’s antibody platform and are incrementally more positive on ABCL’s future pipeline potential.” -Truist https://t.co/t4v5AjfKLR
2 867Views
79Likes
2Reposts
1Replies
0Quotes
1Bookmarks
Is that a lot?
1.00×vs this author's median2 867 views is typical
33Percentile for this authorof 3 recent posts
1.33×vs 10K–100K median2 151 views is typical
18.10%Reachviews ÷ followers
2.86%Engagement rateof viewers reacted